Walid Kamoun, Vice President, Global Head of R&D Oncology at Servier, shared a post on LinkedIn:
“I am thrilled to announce that Peter Adamson will be joining Servier Oncology R&D to lead our oncology clinical development team.
Peter Adamson, MD, FASCO, is a globally recognized physician-scientist and executive leader in oncology drug development and clinical pharmacology. A Professor Emeritus at the University of Pennsylvania, he has led Phase 1–3 trials and cross-sector R&D programs across academia, industry, and government.
Before joining Servier as Global Head of Clinical Oncology Development, Peter served as Global Head of Oncology Development at Sanofi, leading more than 15 global development teams spanning early- and late-stage assets. His portfolio included ADCs, cell and immune therapies, and cytokines. He guided business development efforts across the U.S., Europe, and China and helped integrate four acquisitions. Under his leadership, Sarclisa achieved six global approvals.
In academia, Peter was Chair and CEO of the Children’s Oncology Group (COG), where he launched Project:EveryChild, now the world’s largest ongoing pediatric cancer research initiative. At Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania, he founded a cross-disciplinary drug development division, co-led an NIH-funded translational science center, and created the Rolling Six phase 1 trial design.
Peter was appointed by President Barack Obama to the National Cancer Advisory Board and served on the Cancer Moonshot Blue Ribbon Panel. He has advised more than 15 cancer foundations and played an instrumental role in shaping U.S. childhood cancer policy.
He earned his MD from Cornell University Medical College and a BA in Chemistry from Wesleyan University. He completed his pediatric residency at the Children’s Hospital of Philadelphia and a fellowship in Pediatric Hematology/Oncology at the National Cancer Institute (NCI).”
More posts featuring Peter Adamson.